<SEC-DOCUMENT>0001193125-22-086678.txt : 20220328
<SEC-HEADER>0001193125-22-086678.hdr.sgml : 20220328
<ACCEPTANCE-DATETIME>20220328162018
ACCESSION NUMBER:		0001193125-22-086678
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220328
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220328
DATE AS OF CHANGE:		20220328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acumen Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001576885
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				364108129
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40551
		FILM NUMBER:		22775712

	BUSINESS ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		925-368-8508

	MAIL ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d302531d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abos="http://www.acumenpharm.com/20220328" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-03-28_to_2022-03-28">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-03-28_to_2022-03-28">0001576885</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="abos-20220328.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-03-28_to_2022-03-28"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001576885</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-28</xbrli:startDate> <xbrli:endDate>2022-03-28</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-03-28_to_2022-03-28">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt:datemonthdayyearen">March 28, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-03-28_to_2022-03-28">Acumen Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-03-28_to_2022-03-28">001-40551</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-03-28_to_2022-03-28">36-4108129</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-03-28_to_2022-03-28">427 Park St.</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-03-28_to_2022-03-28">Charlottesville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-03-28_to_2022-03-28">22902</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-03-28_to_2022-03-28">(434)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-03-28_to_2022-03-28">297-1000</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-03-28_to_2022-03-28">Common Stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-03-28_to_2022-03-28">ABOS</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-03-28_to_2022-03-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;2.02 Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;28, 2022, Acumen Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold">Company</span>&#8221;) reported financial results and business highlights for the year ended December&#160;31, 2021. A copy of this press release (the &#8220;<span style="font-weight:bold">Earnings Press Release</span>&#8221;) is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02 of this Current Report on Form <span style="white-space:nowrap">8-K</span> (including Exhibit 99.1) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d). Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d302531dex991.htm">Earnings Press Release, dated March&#160;28, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Acumen Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dated: March&#160;28, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Zuga</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Matthew Zuga</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-style:italic">Chief Financial Officer and Chief Business Officer</span></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d302531dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g14a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December&nbsp;31, 2021 and Business
Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic
amyloid-beta oligomers (A&szlig;Os) to enter clinical testing </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currently enrolling <FONT STYLE="white-space:nowrap">INTERCEPT-AD,</FONT> a multi-center, randomized,
double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer&#146;s disease</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> clinical trial design was presented at 2021 Clinical
Trials on Alzheimer&#146;s Disease (CTAD) Conference in November 2021</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Topline results from <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> now expected in the first half of
2023 </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acumen team expanded and Kim Drapkin appointed to the Board of Directors to enhance depth and breadth of
expertise at the company </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>$225.9</B><B></B><B>&nbsp;million in cash, cash equivalents and marketable securities at
December</B><B></B><B>&nbsp;31, 2021, which is expected to provide cash runway through 2025 </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Company to host conference call and webcast today at 4:30 pm ET</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charlottesville, Va. and Carmel, In., March</B><B></B><B>&nbsp;28, 2022</B> &#150; <U>Acumen Pharmaceuticals, Inc</U>. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer&#146;s disease (AD), today reported financial results for the full year ended December&nbsp;31, 2021, and provided recent business highlights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;After a transformational year in 2021, highlighted by multiple accomplishments, including our IPO, Acumen is completely focused on executing our
business strategy with a primary emphasis on <FONT STYLE="white-space:nowrap">INTERCEPT-AD,</FONT> our Phase 1 clinical trial investigating the safety, tolerability, pharmacokinetics and target engagement of ACU193 in early Alzheimer&#146;s
patients. Based on current progress in the trial and our current plan to report a dataset inclusive of Cohort 7 Day 168 follow up, we now expect to report topline results in the first half of 2023. We have experienced slower than anticipated
enrollment due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, however our strong cash position has provided us the ability to expand the study footprint to support recruitment and to include a longer
<FONT STYLE="white-space:nowrap">follow-up</FONT> period prior to read out,&#148; said Daniel O&#146;Connell, President and Chief Executive Officer at Acumen. &#147;With the proceeds from our successful IPO last year, we estimate our existing cash,
cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital requirements through 2025 based on our current plans.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Business Highlights and Anticipated Milestones </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACU193 Clinical Development </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> enrollment continues to progress.</B>&nbsp;Patient
screening and enrollment is ongoing for <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> at eight active sites, with six additional sites selected for potential activation. Acumen anticipates topline results from this trial in the first half of
2023, subject to the rate of site activation and patient recruitment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Clinical trial design for <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> presented at 2021 Clinical
Trials on Alzheimer&#146;s Disease (CTAD) Conference. </B>The presentation included the scientific rationale for targeting toxic A&szlig;Os, the clinical trial design of the Phase 1 <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> study of
ACU193, and how the study is designed to establish Proof of Mechanism for ACU193 and serve as the basis for moving to a Phase 2/3 trial.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2/3 clinical trial preparation activities progressing. </B>Given the continued advancement of necessary
actions for the planned Phase 2/3 trial, including chronic toxicology and chemistry manufacturing and controls (CMC) activities, Acumen plans to be ready to initiate a Phase 2/3 trial on the success of
<FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> results. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fourth quarter of 2021, Acumen expanded its team with several new appointments. The new team members include <B>Julie Bockenstette</B>, Head of Human
Relations; <B>Siew Tin Gan</B>, Head of Clinical Operations; and <B>Stephen Reynolds</B>, Corporate Controller and Treasurer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We welcome Julie,
Siew Tin and Stephen, who are joining Acumen at a critical time in our company&#146;s growth as we continue to pioneer a new approach to treating Alzheimer&#146;s disease,&#148; said Daniel O&#146;Connell. &#147;We believe their individual
experience and collective passion for improving the lives of patients with Alzheimer&#146;s disease will help us move closer to our ambitious goals.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Bockenstette has more than 20 years of experience in human resources and sales at high-growth companies.
Prior to this role, Bockenstette was Vice President of HR and Head of HR at the Diabetes Care Europe and North America division of Roche Diabetes Care. She has also held several key human resources and leadership roles at Elanco Animal Health and
Eli Lilly and Co., both in Indiana. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Gan has more than 20 years of experience in clinical research with a history of working in the
pharmaceuticals and nutrition industries. Prior to this role, Gan was Senior Clinical Operations Program Leader in Neuroscience at Takeda, in addition to senior research and leadership positions at Danone Nutricia Research (Singapore), Lundbeck
(Singapore), and Novo Nordisk (New Jersey). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mr.&nbsp;Reynolds has more than 25 years of finance experience in the healthcare industry. Prior to this role,
Reynolds was Global Controller and Treasurer at Envigo RMS in Indianapolis, in addition to several other financial management positions at Roche Diagnostics, LDI and FinishMaster, Eli Lilly and Co., Memry Corporation, Roche Health Solutions, and
Assembly Biosciences. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to these appointments, <B>Kim Drapkin</B>, CPA, has been appointed to the Board of Directors effective
April&nbsp;1, 2022. Ms.&nbsp;Drapkin is currently the Chief Financial Officer of Jounce Therapeutics. Ms.&nbsp;Drapkin brings more than 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies,
including building and leading finance functions, raising capital, and leading strategic financial planning. Ms.&nbsp;Drapkin will also serve as the chair of the company&#146;s audit committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I&#146;m incredibly excited to join the Board of Directors of Acumen at this exciting time. We face a massive unmet need in Alzheimer&#146;s disease,
and I believe that Acumen&#146;s approach of targeting toxic amyloid-beta oligomers has the potential to transform the treatment of the disease. I look forward to working with the team and the rest of the Board to support the company&#146;s growth
and, in particular, the development of ACU193,&#148; said Ms.&nbsp;Drapkin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Financial Results </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash Balance.</B> As of December&nbsp;31, 2021, our cash, cash equivalents and marketable securities totaled
$225.9&nbsp;million, compared to cash and cash equivalents of $43.8&nbsp;million and no marketable securities as of December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development (R&amp;D) Expenses. </B>R&amp;D expenses were $12.3&nbsp;million for the twelve-month
period ended December&nbsp;31, 2021, compared to $8.0&nbsp;million for the twelve-month period ended December&nbsp;31, 2020. The net increase in research and development expenses in 2021 from 2020 was primarily due to increased costs related to
initiating our clinical trial in 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General and Administrative (G&amp;A) Expenses.</B> G&amp;A expenses were $7.3&nbsp;million for the
twelve-month period ended December&nbsp;31, 2021, compared to $1.4&nbsp;million for the twelve-month period ended December&nbsp;31, 2020. Following the initial public offering, we added a number of new personnel and a large portion of the other
increase is a direct result of our transition from a private to a public company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Loss from Operations.</B> Losses from operations were $19.6&nbsp;million for the twelve-month period ended
December&nbsp;31, 2021, compared to $7.9&nbsp;million for the twelve-month period ended December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net Loss. </B>Net losses were $100.6&nbsp;million for the twelve-month period ended December&nbsp;31, 2021,
compared to $7.3&nbsp;million for the twelve-month period ended December&nbsp;31, 2020. Net losses in 2021 include a <FONT STYLE="white-space:nowrap">non-cash</FONT> expense of $81.2&nbsp;million that represents the changes in fair value of
Acumen&#146;s Series B tranche liability and Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant liability. The tranche liability and warrant liability were initially recorded at fair value as liabilities on Acumen&#146;s balance sheet and
were subsequently <FONT STYLE="white-space:nowrap">re-measured</FONT> at fair value at the end of each reporting period. The increases in the fair value of these instruments were recognized as a component of other expense. The second tranche of the
Series B Preferred Stock financing round closed in June 2021 and, as a result, the remaining value of the tranche liability was reclassified to convertible preferred stock on </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top">Acumen&#146;s condensed balance sheet. Additionally, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant was exercised in June 2021, and the remaining value of the warrant liability was reclassified to convertible
preferred stock on Acumen&#146;s condensed balance sheet. Upon the closing of the initial public offering, all outstanding shares of convertible preferred stock converted into equivalent shares of common stock. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Details </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acumen will host a conference
call and live audio webcast today, March 28th, at 4:30 pm ET. The live webcast may be accessed from the Investors section of the Company&#146;s website at <U>www.acumenpharm.com</U>. Please connect to the website prior to the start of the conference
call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1&nbsp;877 <FONT STYLE="white-space:nowrap">311-0573</FONT> in the U.S., or +1 470 <FONT
STYLE="white-space:nowrap">495-9505</FONT> outside the U.S., and entering passcode 3629669. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company&#146;s website at <U>www.acumenpharm.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ACU193 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACU193 is a monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble A&szlig;Os, which Acumen believes are the most toxic and
pathogenic form of A&szlig;, relative to A&szlig; monomers and amyloid plaques. Soluble A&szlig;Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting
toxic soluble A&szlig;Os, ACU193 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in AD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 62 individuals with early AD (mild cognitive impairment or mild dementia due to AD) are expected to be randomized into this double-blind,
placebo-controlled, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study of ACU193. <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> is designed to establish safety and proof of mechanism. It
consists of single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts and is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of intravenous doses of ACU193. The study is enrolling at multiple
investigative sites located in the United States. More information can be found on www.clinicaltrials.gov, NCT identifier NCT04931459. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Acumen
Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acumen Pharmaceuticals, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage
biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer&#146;s disease. Acumen&#146;s scientific founders pioneered research on toxic soluble A&szlig;Os, which a growing body of evidence indicates are primary
triggers of Alzheimer&#146;s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble A&szlig;Os, in a Phase 1 clinical trial
involving early Alzheimer&#146;s disease patients. For more information, visit www.acumenpharm.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.&nbsp;Any statement
describing Acumen&#146;s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an <FONT STYLE="white-space:nowrap">at-risk</FONT> statement.&nbsp;Words such as
&#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;would,&#148; &#147;seeks,&#148; &#147;aims,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;will&#148; and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen&#146;s business, Acumen&#146;s ability to achieve its strategic and
financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources, and the therapeutic potential of Acumen&#146;s product candidate, ACU193, including its potential for
improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> trial and Acumen&#146;s planned Phase 2/3 clinical trial,
including the expected timing of initiation, enrollment and reporting data, and risks and uncertainties relating to the progression and duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and responsive measures thereto and
related effects on Acumen. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing
and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. These and other risks concerning Acumen&#146;s programs are described in
additional detail in Acumen&#146;s filings with the Securities and Exchange Commission (&#147;SEC&#148;), including in Acumen&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2021,
and future filings and reports by Acumen, including Acumen&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021. Copies of these and other documents are available from
Acumen.&nbsp;Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update
or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@acumenpharm.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin298784_2"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, short-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; no shares authorized, issued and
outstanding as of December&nbsp;31, 2021; 711,203 shares authorized and 477,297 shares issued and outstanding as of December&nbsp;31, 2020; liquidation preference of $1,067 as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, $0.0001 par value;
no shares authorized, issued and outstanding as of December&nbsp;31, 2021; 11,898,177 shares authorized and 7,537,879 shares issued and outstanding as of December&nbsp;31, 2020; liquidation preference of $16,847 as of December&nbsp;31, 2020</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.0001 par value; no shares authorized, issued and
outstanding as of December&nbsp;31, 2021; 29,457,450 shares authorized and 11,862,043 shares issued and outstanding as of December&nbsp;31, 2020; liquidation preference of $45,070 as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and
outstanding as of December&nbsp;31, 2021; no shares authorized, issued and outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 300,000,000 shares authorized and 40,473,270 shares issued and
outstanding as of December&nbsp;31, 2021; 50,500,000 shares authorized and 419,124 shares issued and outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">352,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin298784_3"></A>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Grant and other revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights liability and preferred stock warrant
liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,057,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">419,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g302531g0328140030882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin298784_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights liability and preferred stock warrant
liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of premiums and accretion of discounts on marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-cash expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series B milestone shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock upon initial public offering, net of issuance
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of preferred stock tranche rights liability upon share issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of warrant liability upon exercise of preferred stock warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible preferred stock into common stock upon IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>abos-20220328.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 3/28/2022 10:44:51 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:abos="http://www.acumenpharm.com/20220328"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acumenpharm.com/20220328"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abos-20220328_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abos-20220328_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>abos-20220328_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 3/28/2022 10:44:51 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>abos-20220328_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 3/28/2022 10:44:51 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abos-20220328.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g302531g0328140030882.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g302531g0328140030882.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O .@# 2(  A$! Q$!_\0
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?[(K,A)1B,E<C!QZ<5,*KBFNC'*"DT^P^BBBLBS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g302531g14a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g302531g14a10.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MVW*M9==5'U/HNOMSU0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M4J'/Y]G/&#][#Y4^6*34Z\HZWNU^Z3;25M>>2OKI%63/+KXZWNT=$MY/]/\
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MG(85^SV<V"$;YMH[Y'K8SA;-,#AJN+K^Q5&@DY<M1N5FU%67*KZM=3S\+G^
MQ=>GAJ/M/:5&U'FA9:)O5W=M$?;=?.'M!0!\K?'+]L;X,_L\^*].\&?$2X\2
MPZUJGAZU\3VJZ-H3:I:_V7=ZEJNE0F2<746R?[7HUZ#'M.%"-GYL#V\MX?S#
M-:$\1A%3=.G-TWSSY7S*,9/2STM-:GE8[.,'E]6-'$.:G*"FN6-URMRBM;K6
M\6>@_ WX\^ ?VAO"NI>,?AU+J\NC:5X@N?#-TVLZ:=+N1J=IINEZI*(X#-+O
M@^R:Q9XDW#+%UQ\N3RYEEF*RFO##XM1C4G!5%R2YERN4HK6RUO!Z'1@<?A\?
M2E6PSER0FX/F7*^9*,MM=+21TOB/XH^#_"?CSP!\.==OGL/$7Q+MO%,WA'S4
M1;"_N/",>CSZEICW32@PZE+;:S%+;1>65F%I<*'601)/C1P6(KX7%8NE'FHX
M-TU5M\455YU&5K?"G!J3OI=:6NUK4Q5&C7P^&G+EJ8E3]GV;I\K<;]':5TNM
MGULGZ'7(= 4 % !0!YI\1_BUX+^%1\%Q>++VXAN_B!XW\/\ P^\*V%C:M=WF
MH^(?$5XEI:@QAD6WT^W#&:YNI75(T4*N^::&&;LPF!Q&-^L>PBG'"49UZC;L
MHTZ:N_63VC%:M]DFUS8C%T<)[%56TZ]2%*FDKMSF[+T2W;>B7=M)^EUQG2?G
M]=_\%+_V7;&[NK*?5?&8GL[B:UF"^$+ME$MO(T4@5A<?,N]#@]Z^ICP=G4HQ
MDH4K22:_>K9ZKH> ^)<KBW'GJ)Q=OX;Z:=RO_P /.?V6/^@MXU_\(Z\_^2*?
M^IN=_P#/NC_X-7^0O]9LK_GJ?^"W_F'_  \Y_98_Z"WC7_PCKS_Y(H_U-SO_
M )]T?_!J_P @_P!9LK_GJ?\ @M_YGLGP0_;#^"_[0?BO4/!GPYO?$-SK>E^'
MKKQ/=)JV@3Z5;+I5EJ6DZ5,Z7$LK!YQ=ZS8@1@9*L[9^2O/S+(,PRJA#$8N-
M.-.4U37+-2?,XRDM$MK0>IV8'.,%CZLJ.&E-SA!S:E!Q7*G&+U[WDM#V'XJ?
M%#PK\'/!6H?$#QK+>6_AK2;[0;'4;FQMENIK0:_KNF^'[:[D@::,M:076IP2
MSE"SK#'*T<<CJL;\&!P5?'XB&%PR3K24W%2=D_9PE-J]GJU%J/2]KM+4[,5B
MJ6"H2Q%9N-.#BFTKVYI*"=M-$VF^MKV3V.XT_4-/U:QL]3TJ^L]3TR_MH;RP
MU'3[F&]L;VTN$66WNK.[MG>*YMI(V5TDC=E96!4D&N:4)4Y2A.+A.#:E&2:<
M6M&FG9IKJGL;QE&45*$E*,DFFFFFNC36C79HN5(PH ^9OC5^UQ\%?V?O$>F>
M%?B3K&L:=K&K:)%X@LH=.\/ZEJT+Z9+?7^G)(\]G&R1R?:M-NE\LG< JGHPK
MV,NR+,<THSK8.G"5.G/D;E.,'S*,9;/RDM3S,;FV"R^I&EB9RC.4>=)0;]V[
MCNMM4SQS_AY?^RB/^9H\4?\ A%:[V_[85Z'^I^>+_ES3_P#!T/\ ,X_]9<J7
M_+V>G_3N7^1]^5\N>^% !0!B>(O$.F>%])NM9U68PVMJO"J-TUQ.P(AM;=,C
M?/(PVJ"0!RS%55F'3@\)6QN(IX;#QO.7R48K>4GTC%:OKT2;:1R8['8?+L-4
MQ6)ERTZ:V7Q2E]F$5UE)Z+9=6TDVN1^%WQ*TKXH>'9=9TZ(VEU8:E>Z1J^FM
M*)9+&^LI2%Q($3S(+BV,%Q&X7I,4)WQOCT,[R:ODF+CAJKYX5:<*M*HE93A-
M=KNTH23A)7W5]FCAR+.J&=X)XJE'V4Z4Y4JM-N[IS@]-;*\91<9Q=MG;>+-3
MQ]X]\/\ PY\/7/B'Q!<B**,216%FF?M.JZB()I[?3;10I_?R^2PWMA(P"[LJ
MJ37G87"U<75C2I+73F?2,;I.3\E?U>R/7G-4XW>EME^A^&'[4GQSU?QQJ]V;
MIS::IJUO:Q+9Z?=72VN@Z+;>6J6MN\DK/YMZT,K3!2BR>=<,R*DRI7Z1DV6T
M\+3BH^]"#>LDKSF^KLOLW5NUEJVFSP<?B6_<6DI)7L]EV^?7R]3XCKZ$\D_1
M/_@GG\8;#X>^*_B%X7UJ1_[.\3>&[76M-B3SI))O$'ABZ>*'3K6-5:.%[S3=
M:OY))I-B@:1$&;A17P7']6A@,JIYK63:PD_9N,5=R]JO=5TM/?A&*;M%<[;/
M2RW$QP\JL9?#**:7]Z.R7JF]?(^TO''Q'USQO.OVIO[/TN!0(M)M9Y3:;E=G
M%Q=%B/M5R 5&]E55"#8BDL6_F3-\]QF;37M'[##Q7NT82?)>]^:=[<TME=I)
M)>ZE=WVKXB=9Z^[!;13T]7W9\R^*/%9O1+ING';9@A9K@%E>XVDY1,$8MR<9
MR,MM[+PWPF/S#VO-0HZ4UO+6\K=%_=_/TW\'%8OGO2IZ06\N_DO+\_0X*O)/
M//U+_9D\%OX4^&=C>WEK'!JGBJXDUZ=F@1+M=/F2.'2+>68#>\'V.%;M(V.$
M.I2X 9GS_0? 65O+LAHU:M-0Q&/D\1)\J4_9M*-&+ENX\D?:1B](NK+1-N_V
MV38?ZO@XRE'EG7?.]+/E>D$WO:RYDNG,_,]'^*WQ!TWX3_#;QM\1]6@-U9>#
M/#NI:XUBLRVSZC<6D#&PTN*X>-U@FO;YK:T21D<*]RI*D#!^_P #A9XW%X;"
M4WRRKU(PO:_*F_>E;2ZC&\FM-$=V*Q$<'AJV)DKQH0<K7M=I:1OTYG9?,_DL
M^(GC76OBQ\1O%GCK4[9$UKQSXFU#69-/LVFE@MIM5O&>VTNR-P[RM;6T;PVL
M(=BVR% >E?N>$P]/ X2AA:;_ '>%IQ@I.R;4%K)VTN[.3MU;/R?$5IXK$U:\
ME:=>;E9=+O2*OK9:)>2*/CWP+XE^&?C'Q!X#\86']E^)/#&H/IVJV:S17$<<
MRI'-%+!<0LR36TUM-#/%(IPT<R-QG O"XFCC,/2Q.'ES4:T>:+M;3;5/9III
MKHT37H5,+6J4*L>2I2=I+\59K=-6:\C^G']B[XX6OQT^ _A;7)#Y?B3PK#!X
M)\7VSW,EU-_;6@6-I#'J;S3(LDBZIISV6HY._9)>30>9(UNSM^-\0Y;++,SK
M4E_!K-UJ3M9<DVWRV6GN2O#IHD[*Z1^FY+CEC<!2GM4HI4ZBO?WH)+FU_F5I
M>K:N['UA7AGJA0!\"?MO_MDQ?LVZ-8>$O"%M;:I\5/%NEW5[IANO*ET[PCI
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M?\%9_P#DN_@#V^$FG?\ J8^,J_4N!O\ D68K_L*E_P"FJ1\!Q9_OV'\J"_\
M3E0_+A5^4?YZ&OM-OD?+V_ _M*K^>3]G"@"&XN(+.":ZN94@M[:)YIYI&"1Q
M11*7>1V) 554$DGTJH0E.4:<(N4Y-1C%*[;>B27F3.<*4)5)R4(4TY2DW912
M5VV^B21\+?$WXC7/C3472WEN+3PW8D&RLI6$:R21+('U*[121Y[*[A06811\
M##-(7_4,DR>&644YQC/&5/CFE>R=K4X-_95E>R7-+5Z**7X]G^>5,WQ')2E*
MG@:37LZ<G:[5U[6:7VG=I*[Y(Z+5R;^;?@+\:;GX6^,;B>_EF;PAX@DE/B+3
MX84N)5F2.X?3[^S#%62ZAN)1&P#JCQ3R!U+)$T7UW%G#U/-\K_=0OC\#&]"5
MVKQ7+[2FTKIJ<8WCI=34;-)R4O$X0S^>49K&G4FHY?CYJ%>+M:+=U3JINW+R
M2E:3O9P<KIM1<<#XZ_'+4O%USJ7B/7KN:#P]ILMRWAOPXTT*1VJR(J06L?EQ
MJ+G4K@0H9)W$C L^"L,85?@<MRV&&C"C2BG5DE[2I9ZVW?E%7T6GWL_:<17M
M%SD[1C\,?R7J?FEK&KWVNZC=:IJ,OFW5T^YR %1%4!(X8D'"11QJJ*/1>222
M3]93A&E!0@N51/ G.4Y.4G=O^OP,RK).N\!>(W\)>,O#.OK>"PBL-9L#>7#.
MD<?]FSW"6^I0RM)\HBEL);B)L]!(2"& (\/B7+:>;9!FV7U*/MG7PM;V4;-O
MV\(.="44M7*%6,)12W:LTTVF>TC1M.4E",=VW;\S]%_$_BEM2+6.GNR6"G$D
M@^5[I@?KD6XP"!P6ZMV _@;'8]UFZ5%N-*.[V<FORCV77J<^*Q3J?NZ;Y::W
M>W-_P/Z9Q%>6<)ZG\&O D_Q!\?Z)HH1&TZUGCU?7'EC:2$:1I\T4EU"X7^*Z
M)CM$R0-]TI/ -?0\+Y1/.LYPF%LG0I25:NVFX^QIRBYQ:76II35]+S3>B9W9
M=A7B\53I6]R+YIWVY(M77_;WPKS9^OJJL:JB*J(BA410%5%485548"J   !T
MQ7]+)**22Y5'1):));:=+'WR5M%HELC\<?\ @JO\<;O3]+\*? ?P_J5JL>NI
M_P )7X_AMIU>^%E87,)\*Z-=QQR$6]K/?1W.I21RH)';3-.D0K&6$WZ#P1EL
M93KYG5@[TOW5!M65VG[2:[M*T$UHN::>NWQW%6.<(4L!3DES^_52>MDU[.+[
M)M.33U]V+6F_PI^P7\#)?C5\>] >^@@D\(_#I[7QQXI%RLC17::;>1#1-%1$
M7;++?:Q]G+QR,BFTL[YLLR+')]+Q-F2RW*ZJBVJ^+O1I6W5T^>?DHPO9J_O.
M/>Z\/(<"\;CZ=TO8X:U6=_)^['_MZ5M']E2]#Z=_X*K_  7GT;QOX6^-^D6&
MW1_%]A;^%/%=S AVQ>*]%AF;1KN];/\ K+_PY$MK'@8"^&&SAG&_QN",P53#
M5LMJ2_>8>3JTD_\ GU-KG2_P5-7_ -?#T^*L$Z=>EC81M"JE3FU_/!>ZW_B@
MK+_ >6_\$U_CU>_#3XR0?#&^$$GA+XOW=II<KSSK ^D>*;"UOV\/7UJS@K-]
MMFE.ER6^4,C7MI(K%K413=O%^5QQF7O&1NJ^ 3DDE?FIMQYXOMRI<Z>MN62^
MU=<O#>/EA<8L*[>QQ;4=7;EFD^1K_%\#76Z?2S_HPK\F/T09++'!')--(D,,
M*/+++*ZQQQ1QJ6>21V(5$5026)  !)Z4TFVDE=O1)?AH#:2[)'\?GQ:^(&N?
M%GXG>,O'FLW=SJ.H>*/$5_>6PD9Y6M]/>Y>+1M*M$Y*6MGIRVEI!$N=L<"*,
MGD_O6 PM/ 8+#X6G%0A0IQ3Z>]:\Y/SE*\F^[/R'%XB>+Q-:O-N4JLVUY*]H
MQ7E%6279']&/[$/[-OA_X&?"7PWK%YH(M/BAXTT"PU;QMJE_#(FKV?\ :.-3
MM/"WE2NW]G0:;#/!;SPQA#+<VTDDN2L:Q?DW$>;U<QQU6G&KS8+#3E&C&+]Q
M\ONNI=?$YM-IN]HM)=;_ *)DF6T\#A*4W3Y<56@I5)/XE?50U^%15DTMY)M]
M+?:M?.GM!0 ?T_2C;R#]#X&_X*6\?LG^*_\ L9?!0_+Q!:_X5]1P?_R/*'E3
MK?\ I#/!XETRJKT]^G_Z6C\7_P!A+_D[3X,?]AW5_P!/"FOU^A<3?\B+,/*$
M/_3L#XS(O^1M@O\ %+_TW,_J9K\5/U$* /Y[_P#@K'_R<1X*]O@OX>_#_BN/
MB)7ZIP-_R*<1_P!A<_\ TS0/S_BO_D84/+#P_P#3M8^T?^"3@Q^SMXT/_5:?
M$(_+P-\.O\:^>XX_Y&V&\L)3_P#3U<]GA/3+JW3_ &B?_IJB>'_\%?3_ *5^
MS\/2W^*)^F9/A[_A7I<!:1S3UPW_ +G.'B[1Y?Y*O_[B/&OV*_$.N>$/V8?V
MT?%'AK4[K1M?T'1O FIZ1JEDXCNK"_LE\4S6]Q"Q!4E7 RK*RL,JRLK$'T.(
M:5.OG/#U"K!3I5)UHRB]G%^S33./):DZ.69S5I2<*E.-)QDMTUSV9^EO[$/[
M6>F?M$>!8/#_ (@O&B^+7@S2[&#Q;!=+:6__  DL(WVT7BW28[6.&*1+@P*U
M[;PP1"TN9PH003V[2?'\1Y'/*<2ZM*/^P8B3=)J[]F]W2E>[7+?W&V^:*WNI
M6^ER3-HX^@J=1VQ="*51.RY^BJ12LM;>\DERM]FCZW\>^/?"7PP\):SXW\;Z
MS:Z#X;T&TDN[^^NF))"*3%:V=N@,M]J%PX$4%I CS32ND<:,S 5X6%PM?&5Z
M>&PU-U:U1I1BOS;VC%;RD[)+5NQZU>O2PM&=:M-4Z=-7;?Y);MO9):MZ(_F$
M_:L_:<\3_M,>/Y-9O!-I?@K09+RS\#>%]^4TS39)%\S4K\(2LVNW\<$$MS)E
MECV)!$?*A!?]ER/)J.3854HVEB*EG6J?S26T8]H1NU%==6]6?F6:YG5S+$<[
MO&C3NJ4/Y8]W_>E9.7;9:(\__9T_Y."^!/\ V63X8?\ J;:'75FVF59GY83$
M?^F9G/EW_(PP'_811_\ 3D3^NNOP@_6S^,CQ#_R,&N?]AC4__2V>OZ#HZ4J7
ME"/Y(_&ZG\2?^*7YL_L,\!C;X'\&#IM\*>'1Z8QI%F*_ \3IB<1Y59_^E,_7
MZ&E"CY0A_P"DHZNL#4* /A__ (*,\?LA?$[_ *_/ ?Z?$'PO7TG"7_(^P7DJ
MW_IBH>)Q%IE&*]:7_IV!_,I%%+,Q2&*25UCEE*1(SL(K>)YYY"J D1QP1R2.
MW14C9B0%)'[$VH[OE6B[:MV7WO1>9^9I/HMOTU?W(_4C]@_]M_5/ASK6C?!_
MXK:Q/J/P[UBYTW1?"_B'6-3ABC^'$Q,MO;0W%S?;5'A*66:VCD,US''IR0B6
M/$"R(/B^)N&X8NG4Q^!IJ&+IJ4ZE.$7^_6C;2C_R]23:LFZC=G[UF?49%G<L
M-.&#Q4W+#R<8PG*27L>B3;_Y=O1.[M!*ZTNC]^K*]L]1L[74-.N[:_L+VWBN
MK*]LIXKJSN[6=%E@N;6Y@=HY[>2)E=)(V965@02#7Y?*,H2<)1<91;3BTTTU
MHTT]4UU3V/OHRC)*46I1DKIIW371IK1H_ 3_ (*S?\EX\ CT^$>F?^IEXT_P
MK]0X&_Y%F*_["I?^FJ1\#Q9IC\/Y4(_^G*A^7\2YC7\?T)K[-NS]#YA;']HE
M?ST?LP4 ?)'QH^)$VH7=UX/T:5X=.L9GM]:G4A3?WD#J&LUXRMK;RH0W(\R1
M3QLC4R??\-Y-&C3IYAB(J5:HE*C'_GW!K2?;FDGI_+'S;M^9\5Y]*M5J97A)
M.-"A)QKR7_+R<7K!=5"#5G_-+^[%-_+/BJX%IX;UJ7.W.GW$*G.TA[E/LR$'
ML=\RX]\5]Q@8<^+PT>U2+MY1?,_P1\!B)<E"J]K0DETU:LON;/EBOMSYP\%^
M*^O7>HR:;81[5TJR\W#*P=KK4$9XVG8@ )$EJT:1J"V29G+$.JQ_!5H8=8[&
MU,.[QE4=MK+9RY;:.+GS-/M96TN_VW+'C(Y1EE+&+EJPHQTU3LM*:FGJIQI<
MBDG]J[\EX[0=9'++%;QO+,ZQ11J6=VR JKU) !)^@!)Z $T:[)7?1+\")SC3
MA*<WRQBKMGF.M:U+J4IB0E;&*3=!'MVERJE!+*,G+X+[1_"'(ZDD]]&BJ=I-
M?O&K/R5[V7W*_=KM8^<Q>*EB)V^&E%^[';RN_/\ +;N?H[\*O%)\7^!="U:3
M(O$M_P"SM1!XS?:=BUFEX)XF").!V$X'45_G_P"(W#BX7XPSC+*?^ZRJ_6<-
MY8?$_O:</6BY2HM]73;V:.NC/GIQ?5:/U6AZ'7PYJ?I'^RE\/%\.^$I?&MU+
MOU#QC&HMH ,+8Z/875Q%"&)4$W%U<*\[8)41K; 8;?7[GX=Y(L%ELLUJ2O6S
M-+DCTIT:<I*/3XJDDYO=<JAUYC[#(\)[##O$R?OU]E_+"+:7S;U]+>9]+>(O
M$&C>$M UGQ/XBU"#2M \/:7?:SK.I7&\P6&F:9;27=[=2"-6=ECMXG;;&K.V
M JJS$ _I-&E4KU:=&C%RJU91A"*W<I.T5\V^NA[-2I"C3G5J24:=.+E)O91B
MKM_)(_D.^+?Q$U;XL?$OQK\1=;E,E_XKUZ\U/:5V"VL0PMM)L(TW-MAL]*@L
MK2,%F(2V7+,<D_O& PE/ X/#82DK1H04?5[REZRDW)^;/R/%XB>*Q-;$3?O5
M9-^BVBO2,4DO)'[Y_P#!-7X)67PX^!MO\0KN!U\5_%WR-:O)'F:1;?POIEQJ
M$'A2SBB'[N'S;>YN]1=UR[_VI$DC?Z.BQ_E_%^8RQ>9/"Q?[C 7@E:W[R2BZ
MC;WT:4%T7*VMW?[WAO!1PV!6(:M5Q=I/RA%M4U;9:-R_[>5]M/H7]K3X,3?'
M?X$^,_ >FQH_B000:_X0$EPEK&?$VAN;K3[5YI2(HDO8OM6GL\I"(-0+LR[-
MR^5D68++,SP^)F[44W"KI?\ =STD[+7W7:5EJ^6VM['H9M@GCL#6P\5^\24J
M>MO?AJE?9<VL=>Y_*Q9W>L>%==M;ZU>YTC7_  WJ\%W;2;?+N],UC1[Q9H7V
M.O[NYMKVW4X8<-%@CBOVR4:=:DX-*=*K%IKI*$E9_)IGY;%SHU$U>%2E)-=X
MRB]/FFC^L?\ 9M^+47QN^"G@'XB-<V$^KZOHL%OXHBTY3%;V7BS31]A\0VJV
MC22/91_VC#+-%#(['R+B!PSI(KO^'9O@7EN8XK"6E&G3FW3YMW2EK3=[)/W6
MDVOM)K1JQ^K9;BUC<%A\1=.<HI32V51:35NFJNEV:-3]H*YO[+X"_&R[TIWB
MU*T^$GQ'N;"2+F6.\@\'ZQ+;21 @YE654*@C[P%1E48RS/+HS7N2Q6'4EY>U
M@G^!>8.4<!C7#24:%9KU5.5C^7S]FBUM+W]HGX%VE]''-:3_ !<^'D<T$RAX
MI@?%>E;898V!$D;N%0J00P8@\&OV;.'*&4YDX.THX6O9K=?NI:^5C\PRQ)YC
M@5)77MZ5U_V_$_KAK\*/UH* "@ H ^!?^"EO'[*'BK_L9O!0_+7[;_"OJ.#_
M /D>4/*G6_\ 2&>!Q+IE57RG3_\ 2D?C#^PC_P G:?!CMC7=8]L8\*:_7Z%Q
M-_R(LP_P0_\ 3L#XW(O^1M@NGO2_]-S/ZF*_%3]1"@#^>[_@K'_R<3X+]O@M
MX=_]3GXBU^J<#?\ (IQ'_87/_P!,T#\_XK_Y&-#RPT/_ $[6/M3_ ().C'[.
MGC/M_P 7I\1'TZ>!OAR/Z5\]QQ_R-L/Y82G_ .GJY[/"FF75O^PF?_IJB>%?
M\%?3_IOP 'I:_$X_G+X!_P *]+@+2.:>N'_*N</%V^7^2K?^XCE/^"<WP\C^
M+'P3_:S^&\FHMHY\9:;X/T.'51!]J&G75UIOC+['>26OF1FZ@ANUA>2$2Q-(
MBNBR1E@Z[\6XIX',<BQ:AS_5I59N-[72E2NKZV;5TG9V>MGL9<.8?ZW@LVPW
M-R>V5.*E:]FXU+.VETG:ZNM.J/@;7]&^*/[(_P ='LUN_P"Q?'WPWUN.ZTO5
MK-99--U2SEB)M;^U6XCC-]H.K:3<,DD,J+O@NYK>9%<2(OU%*I@L]RQ2Y?:8
M7%PM*#MS1:>L7:_+.G):-;-*2=K,\&I#%91CN6_)7PTKQDMFNC5[7C*+U3Z-
MI]3U+]J;]L_Q]^TS_9&BW5I#X2\":3%I=^OA&PF^TQWGBB'3O(U'6-0U!XDF
MO(TN[G4([* A$AMY$+J]PSRGBR3A["Y-[2I&3KXF?-'VLE:U/FO&$8W:6BBY
MO=R6EHV1TYIG.(S+DIM>QH0Y7[-:WG:SDWN]6^5=%YW9]6_!7]BNV\%?LO?&
M+XY?%71E;QS??!OXAZQ\.])DOGDC\,:'J'P[UD6^M:C:6DH@DUV^MKYWCM[@
MS&RB\IF2*]++:>'F'$3Q&=9?EF!J6PT<70A7ERV]I.->%X1;5U"+C9M6YW?5
MPLY>M@LE5#*\9CL5#]^\/5E1C?X(NC*TFEIS23T3ORJVBEM^=G[.?_)PGP(_
M[++\+_\ U-]#KZS-M,JS/RPF(_\ 3,SYW+M,PP'EB*'_ *<B?UU5^$'ZV?QC
M^(/^0]K?_87U+_TLFK^@Z6E*EY1C^2/QNI_$G_B?YGZ&?M9_M%_'3X??&:]\
M*>"OBGXR\,^'--\$_"Y['1M(U>>UL+5[WX;^%KZ[:&!.$:6[N)I6QU:5CWKY
M7(LIRS%9?&MB,%2K595L3><HIR?+B*D5=^222]#Z#-LQQV&QCI4,54I4XTZ%
MHQDTE>C!NR\V[GS7_P -?_M/C_FN7Q$X_P"H_<'I7K_V!DW_ $+:&G]Q'F_V
MOF:_YCJW_@3/Z%?V)/%WB?QW^R_\+O%?C'7-1\1^)-6B\7-J6M:K.US?WAL_
M'GBG3[0W$[<OY5C:6T"YZ) @[5^5<1T*.%SG&T,/2C1HTW2Y815HJ]&G)V7F
MVWZL_0<DK5:^5X6K6FZE27M+RD[MVJS2N_))+T1Q/_!1KC]D+XF_]?O@,?EX
M_P##/^%=/"6F?8/TK?\ IBH8\1:91B?6E_Z=@?B+^PM:6M[^U;\(K&]MH+NR
MN]1\26MW9W4,=Q;75K/X)\2Q3VUS;RJR3021,Z/&ZLK*Q5@02*_1N)9.&1X^
M46XRC&FTT[--5J;336J:>S6Q\3D23S7!Q:33<TT]K>SFFFNWD>\?MR?L.W'P
M0N;CXG?"^SOK_P"$MY,&UNRDEBN+CX?:C>WD=O:VKN76>Z\-W5Q<Q16MPT<C
M6[[;:YE9I()+CS.&N)%F*6"QLHQQT5[CLTJT4KM]E4BE>2NN9>]%:-+NSS(W
M@6\5A4Y81_$MW1;=DN[@V[1=O=>DGJF^V_82_;KD^'TFB_!CXOZA+-X$<VFC
M^!O$@M8Y)O"-S<WCB/3M=N5E62;PRS7"I%/Y<TEB0BM_H?-GS<3<,K%*IF&
M@EB5>5:G?2JDOB@K6516U5TI_P"/XM\BSSZOR8+%RO0TC2G;^&[_  R>_)KH
M[-Q_P[8__!6;_DO7@$>GPBTO_P!3+QK_ (5IP-IE>*_["I?^FJ)'%G^_X?RP
M\?\ TY4/S'MU_<I_P+]&:OLF[/T/F5L?V>U_/9^RGSW\9_B0FE6DWA+19HI-
M0OX'CU:Z@N")=*A+PD6H6-2/M-Q$958%U:.,@[2959/K>&\F=>I''XF+C1HR
M3I0E'2J[/WM?LP=FK)J4NONM/XCBO/EAJ4LLPDE*O6BU6G&6M&-X^Y9+XYQY
MD[M.$>EY)KY$=UC5I'8*J!G=F. JJ"S,Q/8 $YK]!2V27DE^1^8GBWCO7FU"
MSDMX"5LEEB50<J9V5PXE=2 0!M^53T')Y.!]#E>%5&I&4OXEG\E:UE]^K.+'
M2MAY+NXK\;_H?/\ XBU,6=O]DCSY]TC#<&V^3#G:S<<Y;E0!C^(YX .F=8Y8
M:A]7A?VM>+U3MR0V;[WEK%;=7?2S]3A')GC\7]>JV6%P,XOE<;^TJVO&.NB4
M-)R;O]A<K4FX^5ZI81ZC9RVS!0Y&Z%R,^5,OW&'<?W3CLQ'>OC82<))KIT\N
MQ^L5(<\&MG'5>J_SV/&Y_P#1?-^T$0>06$WF$((BA(?>2<+@@BN]-65M4]K?
MA9=^RW/-E*-.+E-J,8[M]#R_6];DU*3RHMT5I"SA$#G]_AB%FD7:N#M"D(0=
MN3SDFN^C15/WI:S:7_;O=+5^C:WL?.8O%RQ$DE[M.%[*^^OQ-::VZ=# KH.,
M^QOV7?$V^V\0>#Y=@,$B^(+(Y/F&.86]A?QX/'EQO'8,,=[B3/:OY9^D/P_R
M5\DXGI7M6B\MKJRY5*G[3$8:5]^:<98B,K_9I0MU.[!STE3VM[R_)_H?<W@'
MPK+XV\9>'?"L3RQ#6-2AMKB>",2RVMBF9M0NDC8@,8;**>7YB!^[YXK^>,FR
MZ6:YI@LNBW%8JK&,I15W"FO>J32V]V"E+730]7"T'B,11H*\?:22;6ZCO)V\
MDFS]EM-T^TTG3['2["%;:QTZTM[&S@0!4AMK6)(((U  &%C11T[5_4-"C3PU
M&CAZ,5"C0A&G"*VC&"48KY)(_0H0C2A&G!<L8)1BNR2LONL?E1_P5+^.MMX;
M\!:-\#-$O\>(?'$UIK_BJ""25)++P;I=V[Z=!<%5"$:IKUF"J"0GR]#N!(FR
M>,M]]P5ECJXJIF52/[K"IPI-VUJR7O-?X(/MO-6=TSY;BC'*EAX8&$K5*]I3
M2Z4XO1/_ !27W1=]T?D'^S?\+/\ A<_QN^'?PZF@NYM+USQ!;OXA^QGRYH?#
M.EH^J>(95GZ6K?V39W2)*>DDL84,[*K?>9OC?[.RW%XM-*=*#]G?;VDO=IJW
M7WFFUV3Z'R&6X7Z[C<-AK-PG-<]OY(^]/7I[J>O<]W_;@^+VJZG\?/$/@_P7
MJ>H>%_ _PDM;+X7>%] \/ZE=Z9I-A#X5C^R:IY%A8S100.NK&[M057=Y&GVL
M;$B%0OF<-X"%/*Z5?$0C6Q..;Q%2<XJ4FZFL;RDFW[MG_BE)]3OSO%RECZE&
MC)TJ&$2HPA"345[/25DK)>]=>B2Z'R(/'GCE?N^,_%BX]/$6L#&/I>5[WU7#
M?] ]+_P7#_(\CV]=?\OJB_[?E_F<O+++/+)--))---(\LLLKM)+++(Q>2221
MR6>1F))8DDDDGDULDHI)+E4=$EHDEMITL9-_>?JQ_P $K/C#;>%OB1XL^$NM
MZLMIIWQ"TVWU3PQ:W3R^1+XPT#S/.LK, &*WN[_0)[N1V<IYQT"VA#&0Q(_Q
M/&V7NM@Z&.I4^:>$DXU&K75*>S?5J,TDK7MSM[79]5PKC%2Q-7"3GRQKI2@G
MM[2'1=$Y0;]>5+>R/WKO+.UU"SNK"^@BNK*^MI[.\M9T#PW%K<Q-#<03(>'B
MDB=T93U#$5^81E*$HRB^646FFMTUJFO1GWCBFG%J\6FFGM;9H_CM\5:'KOPQ
M^(6O^'W>]T?Q%X$\6:AI\<Z,]K?6&I>'M5DBMKRWEC8-%*LUK%/%-&Q'W)$8
M@JQ_?J%2EC,)2JV4Z.)I1E;>+C..J:[6=FGYIGX_5A4PN(J4]85*%1I/9IPE
MHT_*UTU\C^I;]E[XWZ9\>_@YX2\:Q:CIUUXE73+73O'.G6+HDFD>++*+[/JD
M4]CN,EC!=31->6ROPUO=1,C,.:_%<YRV>5YA7PW)*-%2<J,I?:I/6-I;2<4^
M67:2=['ZCE>-CCL'1K*2=112JQ7V:BTE==$[7CY-'T+7E'H!0 4 ?!W_  4F
MLY[K]DSQM+#&SI8:[X)O+C:,^7 ?%.FV7F-CHHFO(1G_ &A7TW"$E'/,,KVY
MH5DO7V<G^29X7$D6\IK67PRIM^G.E^J/Q&_8FU2ST;]JKX*7E]/%;0/XM.FK
M),ZQI]JUK2=2T:QBW,0-\M]?V\2CNTB@<FOT?B*$IY)F,8*[C2YK+M"49O[E
M%M^A\3DDE3S7!.3Y5[3E^<HN*_%I']55?B1^IA0!_.'_ ,%/_%^E>)_VFSIN
MESI/)X&\ >&O"&K-'ED35O[0U_Q3- '^Z[Q6OBBSC?:3LDCDC;#QNJ_K?!F'
MG0R;GFN58BO4JP7]WEA33MTNZ;:\K/9H_.>)ZT*N9\L'?V%*%.7^*\YV^2FD
M_/3='Z+?\$K]&OM+_9HU.^NH9(H/$?Q2\4ZSICNNU;BQ@T7PIX>DFB/\<8U+
M0=0BS_>@<?PU\GQK4C/.(0B]:.&IPDNS<ZM1+_P&<7Z,^BX6A*&62;5E4KSE
M'T480_.#7R/G'_@KX?\ B8? (>EG\2S^<_@0?TKUN O@S3UP_P"58\[B[XL!
MY*M_[B.A_P""0O&B?';_ +"OP]_2T\85EQY_$RS_  U_SI&G"/P8[RE2_*H?
M;G[7?[+'A[]I?P&+/S!H_C[PO'?ZAX*U^*&W)ENWM) ?#NL-(H:30K^=+;>R
M.CV\L,5Q&65)8+GYS(<ZJY-B>:W/A:W+&M"[V3_B0M]N*O;2TDW%]&O;S?*Z
M>8T.7X*]&[ISTWM\$O[LG:_5-)KJG\ ?L$_L,:[9^)W^+GQQ\,2Z/'X6U.^T
M_P )> O$NDJT^HZS9-+9S^)]3MKF7;%86%TCBP1X)A=3*+V-DAMK:2\^IXGX
MEI.BL!EE93]M&,JM:G+2,'9JG%K[4E\=FN5>XTVY*/@9#D=2-7ZWCJ7)[%M4
MZ4XZN2T<Y)[*+^'1W?O*R2;_ %$_:: 3]G#X\@ *%^#GQ(50!@ #P?JX  '0
M 5\7DW_(WRO_ +"\/_Z=@?3YGIEN/Z6P];_TW(_F(_9Q_P"3A?@/_P!EF^%_
M_J;Z'7[+FVF59GY83$?^F9GYEENF88#RQ%#_ -.1/ZZ:_"#];/XQM>_Y#NM?
M]A;4?_2R:OZ#I:4J?2T8_DC\:G\<_P#$_P S^P'PCH^DW/A'PG-=:7IUQ,WA
MCP^'FGLK:65MFD6:+NDDB+':J@#)X  [5^"UZDXUZZC.44JD[)-K[3Z7/UZC
M"#HTKQ3]R&Z7\J.A_P"$?T'_ * FD?\ @MLNW_;&LO:U5_R\DK?WG_F:>SIK
M[$5;^ZO\C1@M[>TB2WM8(;:"//EP01)#$FYB[;(XU"KEV9C@#DD]34-MN[;;
M[O<I)15DN5+9+3\#XC_X*-\?LA_$OM_I_@/VZ>/O#7^%?1\)?\C[!^4:W_IB
MH>)Q%IE&)]:7_IV!^)_[!0_XRW^#/MJ_B#]/!GB2OT7B?3(LP\HP_P#3M,^+
MR'_D;8/_ !3_ /3<S^H/5-*TO7--OM&UK3K'5](U2UGL=2TO4[2"^T_4+*YC
M:*XM+VRNHWANK:6)F1XI$965B""#7XQ"<Z4XU*4W3G!IQE%N,HM:IIJS371K
M8_3I0C.,H3BI0DK.,DFFMFFGHUY,_G9_;H_8OU3X'^(;WXC^ -/EO_A)XBU"
MYNI;73K&Y;_A7%_<W!==(U'RUE2'PY(TT:6%\\B -FSF1'2WDOOUCAKB&&8T
MHX/%24,=1BDG*2_?Q2^*-[-U%;WXI/\ G3:<E'\\SS)IX*H\3AX\V$FV[13_
M '+O\+WM#^67_;KL[.7$?MKO)+9?LD3RR/++-^QY\''DEE9GDDD:+67>21V)
M+NS/DL222<GK73PXE&6>I*RCFN*LO_ $M##.OARG_L7X?_VX^-;1?]'C_P"!
M?H[5]!+1OR/'6B7D?US_ !-^(5MX(TDQVLD4WB"_5H].M=T;FU!5@=1NH6;(
MMHRN%!!\R3"CY5<I^+Y)E$\RQ"<TXX2BTZDM5S;?NXO^9]?Y8Z[N*?Z'Q!GE
M/*,-RTVI8VLK4H:/DW_>SC_+&UEI[TM-E)KX6NKJ:[GN+V\G>>XN)9;FYN)G
MW/+-*[22S2NW5F=F8D^M?J%.G&E"%*E%1A32C&*6B25DDO)*R/QZI4G5J3JU
M).=2I)RE)N[<F[MM]VW=GF7B+76NI&LK1RMK$625T<8NF! (!7K",''.&SD\
M8KV<)AE32J5%[[LTFOA^_K^1G^%CROQ9=PV6E&>8X1)T.T8W,1'+M5 2,L6V
M@=.HSQ7HPKT\*JE:H[0IP;MU;NDHK;5MI(S>#K8^IA\%AE>K7J)*][124G*<
MK)M1@E>32;LM$W9'SM>74M[<27$K%B[':"<[$!.R-?15''Z]37R&)Q%3%5IU
MJC;<F[)_9C?W8KRBM/\ @GZWEV!HY=@Z.$H148THKF:5N>=DIS?5N35W?;1+
M1)&=<W-O902W5U-';V\"-)+-*P2.-%&268_RZGH.:QC%R:C%7;T21USG&E%S
MG)0A%7;>B21\K^,_%7_"1:G/)9K);Z<1$JQ.%62X:)57SIPI/4HNU,D *,_-
MFO<PV&5"*YM9K[EOLOGJSXS'XWZS5E[*\*"VCM=]9-+N]?\ @W.+KK//"@#U
M?X)^(K;PS\1=#NKV?[-8WOVG2+J4L$C0:A"T5L9F8A5@6_6T9V8X4*6/W:_-
MO%K(\1GW N;X;"4?;XS!^RQM&"3<F\--2JJFDFW4>'=:,(I7DVH+XC;#R4*L
M>B>C^>WXV/Z&_P!D+P#!'9:O\0=1L7^V2W#:-X>GG21%CLXXE;5+RT# +*)I
MI8[7SESM^QW$8(WR _S5X:9/"-+$YS7I/VLI.AAI2324$KU9POH^:35/F5[<
MDXIZR1][D&%2C4Q4HVE?DIM]$E[S7JWRW\FNY]G:IJ=AHFF:CK&J7,=GIFD6
M%WJ>HWDQ(BM;"PMY+J[N92 2(XK>*1VP.BFOUF$)5)PITUS3G)1BENVW9+YM
MV/HI2C3C*<GRQ@G)OLDKM_)(_DW_ &EOC1<_'WXR^+OB0T=Y::5J-Q#8>&--
MO_)%SI7AG2H5M-)M)DMY)(HKET62ZG6.251<7MP5=P0Q_<LGRY95E^'P=TYP
M3E4E&]I5).\FKV=E\,;I/EBM$?E.98UX[&5<39QA)I0B[7C"*M%::7ZO5ZMZ
MGZL?\$J/@H=)\,^+OC9X@T 0W_B*ZB\-> ]4O8I4N1X?T\2MXDOM,5\1FQO]
M5:TL_M !<OX?N(U*H7\[XCC;,>>M0RZE5O"@O:5HIJW.[>SC+K>,;RMM::>]
MK?4\*X+DI5<;4IVE4?)2D]^1?&X^4I65_P"XUMO^L[^'M E=Y9=#T>221V>2
M1],LG=W<EG=W: EG9B22222<FOAE5JI)*I-);+F?^9]9[.G_ ,^X_P#@*_R&
M_P#"->'/^@!HO_@JL?\ XQ1[:K_S]G_X$_\ ,/94_P#GW'_P%?Y'Q'^WS^S_
M .%OB+\ ?%/B+3/#-LOC?X:Z=<>*O#-]I5JEM<K8VL]E/XJT^>&TB'VZSGT"
MTNI1$REEN+&VD0C8ZR_1\+YI6P>:4*,ZS^K8N2I5(R=U=IJE)-_"XS:5_P"5
MM/HUXF?9?2Q&7U:D*2]OA4YP<59V33FFENG!-V[I/U_G$\+>)=:\%^)-!\6^
M'+V33M>\-:M8:WI%[%]ZVU#3+F.[M9"N<2()8E#(V5=2RL"K$'];K4:>(HU<
M/5CS4JL90E'O%JS_  V['YS2JSH5*=6D^6=*2E%]G%W7Y']<OP=^*/A_XS_#
M7PC\2O#+_P#$L\3Z7'=/:L<SZ5J<#/::QHUUP/\ 2;#5(+NT=ERCFW\R-FCD
M1F_"<?@JN78RO@ZRM.A*R?24=X37E*+4EU5[.S31^MX/%4\;AJ.)I?#5C>W\
MLEI*+\XR37RNM#\W?^"B?['5[XZMYOCE\+=$LY/$NC:;/)\0= TRTN#K/BZT
M@ELH[37-/M[96CO-6TZQ%V;E"JS7%K;Q^6TLMLD4OUW">?QPK668VHU1G)>P
MG)KDI/6\)-ZJ,G;EZ1DW>R;:^<XAR>5=/'86"]I!/VL(I\U1*UI)+1RBK\W5
MQ2M=I)_D#\)/C;\5OV>_%%QK/P]U^^\-:@TUO!K^C7=N)=+UF/3I9]FG>(-&
MNTVW"Q&>[121'/ ;B4P2PR'</O<=EN!S2BJ6*I*M!)N$T[2A=+WH36U[+O%V
M5TUH?(83&XK+ZKGAZCI2T4HM>[+EOI.+WM=]FKNS3/UP\-?\%</ TNFVO_"8
M?"7Q98:PL2+>CPUJ^CZKIKSJ@$DUJ=4?3IX8G<,PAD$AC!"F60KO;X2MP)B5
M.7U?'4I4T_=]I&<)6Z)\O.FUW5K]EL?6TN+:'*O;82I&:WY)1DOES<K7IK;N
MRSK/_!7#X=06DS>'OA)XTU"^$;_9X=9UG0]&M&E'$8FN+'^TY$C[DK"QXP!S
MD*GP)B^9>UQU&$>KA"<G;R3Y%^(Y\6X=)^SPE24ELI2C%?>N;\B_^Q'^U]\7
M/VDOV@?&>F>,;K2M+\&Z=\-=9UO1/!VB:=;0V.G7\7BOP=86]W/JD\;ZEJ5X
MEC?741::Z$)-Q(T=O%N 6>(\@P&3Y5AYX>,I8B6(A"=6<G=Q]E5DTHJT(KFB
MGI&^BO)E9)F^+S',*T*SC&C&C*4:<4K1:G32?,_>;2;6KMJ[)'Z:?$#P3HOQ
M'\$>*O ?B*WCN-&\5Z'J&B7J21K)Y27MN\45W"&^[=6MP8KF%P0R2V\;J0R@
MCX["XBI@\30Q-%\M2A.,X_)[/R:NFNJ;1]+B*$,10JX>HKPJQ<7\U9/U3U79
MI,_DB\=^"/&OP7^(.J>%/$-KJ7A[Q5X1UIOLUT(KS3I7?3[QFTSQ!HT\J122
M6-QY$5W9WD7#HT<B-7[IA<3A\?A*=>DXU:%>&JNI)77O0FE=*4;\LHO9W3/R
M:O0K8+$2I5$Z=6C+1ZKX7[LXMV=G:\6MU9H_4SX)_P#!56;P[X2T_P /?&CP
M;KGBW7-*B6V7QEX:N]+CO=;MT9A%)K.D7PM(8]1CB"(]S!<E;@C>T,;[FE^+
MS'@E5:\JN78B%"E/7V-12M!]>24>9\K>T6O=V3:LE]1@N*G2HQI8VC*M.&GM
M(.-Y+IS1=E==6GKV3WZOXE?\%9M#G\+ZE9_";X>>(++Q9=1"#3=8\;-I!TK2
MC(V);YM+TG4;E]2N8XMWDPO-#%YA1Y?,CC:&;#!\#5(UH/'8N$J$=90H\W-*
MVRYI1BHIO=I-VT5F[K;$\64_92CA,/.-5Z1E4Y>6/GRQ;NUT5TK[W6C_ !\@
MM_'/Q>\>B*"/5?&?C_QYK[-@$3ZEK>NZO=%Y)9'8I'%OGE9WD<Q0PH"S&.*,
ME?O6\-@,+KRX?"X6'I&$(+1=7HEHE=M]VSX]*OC*]ES5L17G\Y2D_N7X)+LD
M?U9_L\_"^3X+_!7X=_#*>:WN+[PKH"0:K/:;C:3:WJ-U<ZQKDEJSJK/;'6-1
MOC&[*K,FUF522!^(YKC5C\QQ>,2<8UIW@GNH12A"_9\D5?LS]5R_"_4L%AL+
M=-T86DUMS-N4K>7,W8_*_P#X*^'_ (F?P$'I8?$D_G<>!Q_2OMN M(9I_BP_
MY5CY;B[XL!Y*M^=(Z/\ X)"\:'\=NW_$U^'WMTM/%]8\>?Q,L_PU_P Z1IPC
MI3QW^*E^50_9.OS\^Q"@#PW]IWC]G#X]=O\ BSWQ''I_S*.KBO2R;_D;Y7Y8
MK#_^G8G#F>F78_\ [!ZW_IN1_,3^SA_R</\  7_LL_PN_P#4XT*OV3-],IS/
MRPF)_P#3,S\RRW3,,!Y8BA_Z=B?UT5^$GZV?QBZ[_P AO6/^PKJ'_I7-7]"4
MM*=/RC'\D?C4])S\I/\ ,_=+0/\ @JQ\%-)T+1=*F^'WQ2>;3-)TW3Y9(K7P
MF8GELK.&VD>,OXI5O++QDC<JG!&0#Q7YI5X(S&=6I-8K#)2E*23=6]FVU_R[
M/N:?%6"ITX0^KU[PC%;4^B2_G\C6_P"'M'P/_P"B>?%;_P !/"/_ ,U=1_J-
MF7_07AOOJ_\ RHO_ %LP/_0/7^ZG_P#)GHWPD_X*/?";XP_$;PK\--!\%?$3
M3-7\67\NGV-]J]MX:33;:6&RNKYGNVLO$5Q,L9BM'4>7"YW,O&,D<F.X1QV
MPE?&5<10E3H14G&#J<S5U'2]-+KU:.C"<1X3&8BEA:="M&=5V3DH65DWK:;?
M3HCJ/^"CG'[(GQ)_["'@0?EX\\-_X5APE_R/L'Y1K?\ IFH:\1:91B?)TO\
MT[ _%+]@G_D[CX->VK>(OT\%>):_1>)],BS#_#3_ /3U,^+R'_D;8/RE/_TW
M,_J1K\6/U R];T32/$FCZIX>U_3K35]#UJPNM+U;2[^%+BRU#3[V%[>[L[J"
M0%9898)'1E/9JNE4J4*D*M*;IU*4E*$HNSC*+NFGT::)G"%2$J=2*E"2<91:
MNFFK--=FC\-_^"G'P*UOPO\ \*B\6^$]"F;X5^!?AMH/PF2XBN9;^X\.MX>O
M=1.@P:L;AFN#:W&F74$,5\[2AI[.5)WCEF@^T_I/!N94ZWU^A7JI8W$XB>)L
MTHJ?.H\[C;2\9)MQ5K)IQ32=OA^)L#.E]4JTJ?\ LM"C"A>]W#D;Y%*^MG%I
M*6NJ:=FU?\J[%?\ 18O^!^O:1Z^VD[2?D?+1V1_6?XB^#.B^)]7NM:U;7-?>
M\NO+#")],B@ACB18H88(_P"S3LB2-0!DLQ.69F9B3^/8/B/$X'#PPV'PM"-.
MG>UU4<FV[MR?M%=M^BZ)))(^ZQW"F$S#$U,7B<7B75G;X7248J*2C&*]D[))
M=VWNVVVSD]2_9L\+WUN;5/$/B.VC?B;:=+D=U!!" MIXV+P<X!)Z9 SGNH\9
M8^C)3^J8>3CM=54E_P"5#C? V6],7B5;SI/_ -QHYC_AD3P?_P!#1XE'_ -+
MX_\ ).NO_7[-/^@3"KY5?_EI/^HN7_\ 09B/_*7_ ,K.;\0_L1>"O$4=O#<>
M,_%EO#;LT@2WBT;+R,-H9VDL6X51@ 8^\2<\;<,1QMF.(@J<\-AXQ3YFHJHK
MM*RWFWI=[.W=:([LOX4P675I8BE6J5*K@X)U.5\L6TY)**BO><8ZM-JUDTF[
M\M_P[T^'7_0\^-?^_>A?_*ZN/_6C%_\ 0/1_\G_^2/9^H+_GZ_\ P'_@G*>*
M/^"9?PU\4Q6]M=?$GQ_:6MM)YP@MH/#GSSA7C661Y=*8_+&[*%&!\S$Y)&-Z
M'&&-P[;AA*#;5KOVFW;2:[''B\CIXR,85,3.$(.]HJ*UVN[WV3?8XO\ X=)_
M"$?\U.^) Q_TR\,#&/\ N#UT?Z\YBO\ F$PVGE5_^6'!_JEA/^@JM]T/_D2?
M_ATK\&/^BD_$_P#[[\*?_,]4_P"O.:_] V$_\ K?_+A_ZIX+_H)K?^2?_(!_
MPZ5^#'_12?B?_P!]^%/_ )GJ/]><U_Z!L)_X!6_^7!_JG@O^@FM_Y)_\@'_#
MI7X,?]%)^)__ 'WX4_\ F>H_UYS7_H&PG_@%;_Y<'^J>"_Z":W_DG_R!^G?A
M;P[8^$?#>A^&--,K6.A:79Z7;R3E6GF2S@2$W$[*JJ9Y65I'*JHWR-@ <#X3
M"X:C@L/2PN&A[.A0BH0C=NR6VKNWYM]3Z6C2CAZ5.C#2%**BK[Z*UWYO=G,_
M%CX?GXI_#[Q-\/7\2ZSX4LO%FFS:+JVK:!'ITFJ'1KU3!JNG0G5+2Y@BBOK)
MYK65_*+B*XD$;(Y#KZ6!Q7U'%4<5[&%>5"2G",^91YUK&3Y7%^Z[22O:Z5[K
M0C%X?ZUAZN']I*C&JN64H6YN5Z27O)I<RT>E[-VL?G$__!)/X1?\L_B?\1U_
MWX?#+XQ_NZ2E?6KCK'K_ )@L/IYU/_DCYS_5/"?]!596\H?_ ")^F_@;P?H_
MP^\&^%O WA^-XM%\(Z!I/AW2UE;?.UGI%E#90RW$F!YMS(L/F2R'EY)'8\M7
MQV)KU,5B*V)JN]2O.4Y6VO)MM)=$KV2Z(^FH488:C2H4U:%&$81](I)7\W:[
M\SJJP-0H CEBCGBD@FC26&:-XI8I%#QR1R*4>-T8$,C*2"#P02*:;BU;1QV^
M6P-*UNG8_*_6/^"3GP;OM6U*^TSQ_P"/-#TZ[O[NZL=%MTT:]M])M)YWEM]-
M@N[^UDN;F&VB984EN)))66,&1W<EC]K3XXS"%.$9X6C4G&*3F^=.32LY-1:2
M;W:2271)'RL^$\&YR<,15A%MM17*U%7T2;3;MM=MON?:G[./P"T_]G'P-=?#
M_1?%FM^*M$?6[O7+!M=MM.@N=,EOX;>.]M()-.AB$MI)-;"<"12RR32X;:X"
M_.YOFDLVQ,<54H0H5%!0?(Y6DHM\K?,W9I.VG1(]K+<!'+:#P\*LJL.9R7,D
MG&Z5TK6TTOZW/H"O+/0/C7XW?L)? +XY:YJOBW7=*UKPUXTUB./[?XF\):J;
M&:]N;>W2WM[J_P!)OH+O3;F<1QQ+)*MI%-,$^>4MAU^@RWB;-,LIPH4IPK8>
MG\-.K&Z2;NU&47&:79<S2Z*VAXV-R+ 8V<JM2$J5:6\Z<K7:5DW%IQ;[NR;[
MGP1XM_X)&>(H9M_@7XQZ+?V['/V;Q;X;OM(FMP#@+]NT>]U);HXYW?9+?TVG
MK7U%#CNE:V)R^<6NM*HIK_P&:A;_ ,"9X-7A*HG^XQD9+M4@XV^<7*_W(N^#
M?^"1FH-,)?B!\8[."WCEBW:?X-\-SW4US#@F8#5];O;=;*4':%/]FW0()) Q
MM,8CCN"5L+E[;_FJU$DGT]R"=_\ P.)5'A*5_P#:,8DETIPOI_BDU;_P%GZ(
M? ']C[X-?LX:C=:[X!L_$%SXFO\ 0Y/#VH^(O$6N3ZA>WFES7MCJ,\#6-I%:
M:9 7O--L9-\-C&X%N%5@K.'^4S3/\PS:$:6*E"-&,^>-.G!12DDXIW;E-V4F
MK.36OI;Z' 9/@\NDYX=3=24>1SG)MN-TWHK16L5M'IZGU)7BGJ'SU\?/V8/A
M+^T=IVG6OQ%TF^_M/0X;Z#0?$FAZ@^EZ[HZ:AY+7*0RE);6^@,EO#(L%_:W<
M2,&9$5I'+^KE><X[)YR>$FE";BYTYQYH2Y;VNM)1>K5XRB[;MV1Y^/RS"9A&
M*Q$'S4[J$XNTHWM?NFM%I)-+IU/S$\<?\$CO$$5TTOPU^+>C7MDYD*6/CC1K
MW2KJU"@>5&VJZ -0CORS9W.-.L]HQA'K[+#<=TN6V,P$XR76C-23[^[/D<?3
MGEZH^8K\)5$_]FQ<91[58N+7;WH<U_\ P&)!X'_X)'^*9ITD^)/Q:T#3+9.7
MLO ^D:CKD\^" $34]>325M/EW'>;"XY4#9\V5>)X[H15L'@9R?1UI1@E_P!N
MPY[^G,O4*'"56_\ M.+A%+I2BY/_ ,"ER6_\!?H?I?\ L_\ [)GP?_9N&H77
M@#3=3NO$.L6-OINK>*?$=^-2UN[LK>07!M(3#;V]IIMK+=*DTL5E:P"5H(#*
M9/LT7E_'YIGF/S;DCBIQC2IR<H4J<>6";TN[MRDTM$Y2=KNUKN_TN7Y3@\MY
MGAXMU))1E.;O)I:VT245?5J*5[*][(^F*\<](^,?VLOV.]-_:HNO US?^.[[
MP8?!%OXA@B2ST"#6AJ \02:-([2--JMG]F,/]CJ  )-WGG.W9\WT.19_/)(X
MF,,*L1]8=-N\W#E]GSKI&5[\WE:QXV;9/'-'0<J[H>P4TDHJ5^;E[R5K<OXF
MC^R=^R9I_P"RO9>-[*P\;7OC,>-+K0;J5[S0X-$.GG0H=6B1(UAU.\^T"8:H
MQ))CV^2,;MW$9YGD\ZEAI2PRPWU9322FYWYW%]8QM;E\]RLIRF.51KQC6=;V
MS@]8J-N3F723O?F_ ^O:\$]<* .)^)7@R+XC?#SQS\/YM0DTJ'QMX2\0^%)=
M3BMUNY-.CU_2KK2WO8[5Y8EN'A6Z,@C,L88IM++G(Z<'B'@\7AL4H\[PU6G5
M4;VYO9R4K7L[7M:]G8PQ-%8C#U\/S<BK4YT^:U[<T7&]M+VOM='YL_#O_@EK
MH/P_^('@7QY#\9-7U.7P1XQ\,^+HM-D\%V5K'J$GAK6K'64L9+E?$<IMDG:R
M$1E$<A02%@K8P?KL7QK5Q6%Q.%>7Q@L12J4G)5F^7VD'"]O9J]KWM=7[GSF'
MX7IX;$4*ZQDI.A4A44?9I7Y)*5K\[M>UKVT/U<KX@^J/QNO?^"1FGWE[=W?_
M  OJ]C^U75Q<^7_PK:!MGGRO+LW?\)R-VW=C.!G'05^@1X[E",8_V6GRI+_>
M'T5O^?)\<^$HMM_7VKMO^"O_ ):5?^'0>G?]%\O?_#:0?_-U5?Z^R_Z%:_\
M"A__ "D7^J,?^@]_^"5_\M#_ (=!Z=_T7R]_\-I!_P#-U1_K[+_H5K_PH?\
M\I#_ %1C_P!![_\ !*_^6GJWP0_X)HV/P8^*O@SXGQ?&.Z\0OX/U&?4%T5_
MD.E)?F;3KRP\IM07Q==FV"B[W[A;RY\O;CYLCAS+C"6/P.(P7]GJBJ\5'G]L
MY<MI*7P^RC?:VZ.K \-1P6*HXI8QU/8-OE]ERWT:W]H[;]F?:W[17P8B^/\
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DUHD[V25CXROPPU6J?5Z\8T;WA&=W))J]FTM;.Z3WM:^MS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140012226757656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Acumen Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4108129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">427 Park St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABOS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d302531d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abos-20220328.xsd" xlink:type="simple"/>
    <context id="duration_2022-03-28_to_2022-03-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576885</identifier>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-03-28_to_2022-03-28">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-03-28_to_2022-03-28"
      id="Hidden_dei_EntityCentralIndexKey">0001576885</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-03-28_to_2022-03-28">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-03-28_to_2022-03-28">2022-03-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-03-28_to_2022-03-28">Acumen Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-03-28_to_2022-03-28">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-03-28_to_2022-03-28">001-40551</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-03-28_to_2022-03-28">36-4108129</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-03-28_to_2022-03-28">427 Park St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-03-28_to_2022-03-28">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-03-28_to_2022-03-28">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-03-28_to_2022-03-28">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-03-28_to_2022-03-28">(434)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-03-28_to_2022-03-28">297-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-03-28_to_2022-03-28">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-03-28_to_2022-03-28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-03-28_to_2022-03-28">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-03-28_to_2022-03-28">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-03-28_to_2022-03-28">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-03-28_to_2022-03-28">ABOS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-03-28_to_2022-03-28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-03-28_to_2022-03-28">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-03-28_to_2022-03-28">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MQ%^N!8=%Z5Z YTNM[7O#'8?+_V:,_P%02P,$%     @ A()\5)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ A()\5 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "$@GQ4 U#( .T    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "$@GQ4F5R<(Q &  "<)P  $P
M        @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (2"
M?%3;O_EY4 0  -D0   8              " @0P(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "$@GQ4GZ ;\+$"  #B#   #0
M        @ &2#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (2"?%27BKL<
MP    !,"   +              "  6X/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( (2"?%0<.&7J/P$  #P"   /              "  5<0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "$@GQ4)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "$@GQ499!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d302531d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d302531d8k.htm">d302531d8k.htm</File>
    <File>abos-20220328.xsd</File>
    <File>abos-20220328_lab.xml</File>
    <File>abos-20220328_pre.xml</File>
    <File>d302531dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d302531d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d302531d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abos-20220328_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abos-20220328_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abos-20220328.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "abos",
   "nsuri": "http://www.acumenpharm.com/20220328",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d302531d8k.htm",
      "contextRef": "duration_2022-03-28_to_2022-03-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d302531d8k.htm",
      "contextRef": "duration_2022-03-28_to_2022-03-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.acumenpharm.com//20220328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-22-086678-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-086678-xbrl.zip
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M1.]H=G/\.=16BG2*\#YKW"+8'>Y:85S252G8KH7+?:M6#$/P##\8(W$21<J
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M<F4N>&ULU9I=C^(V%(;O5]K_X&9O6JDA!&;:'33,BC(S*]3Y0,"V56]6)CF
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M_\-VR75P4)<';##/OFZ/F'_F24YL^1M02P,$%     @ A()\5(&,[=?H#@
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MH?1[''C1X4C&W^4-*1$T7DZGFTFG5W((A,198+3-0 Z60V=#O/ =XS^'H#H
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M 2'0%T-:!JWZ&.2\(UG'%P/X)<S64]D;Q<*Q)]@I,*S2)@YEV6)P;'W<QQ/
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M<RTR,#(R,#,R.%]L86(N>&UL4$L! A0#%     @ A()\5$80U._0!   1"P
M !4              ( !,@H  &%B;W,M,C R,C S,CA?<')E+GAM;%!+ 0(4
M Q0    ( (2"?%2!C.W7Z X  (!@   .              "  34/  !D,S R
M-3,Q9#AK+FAT;5!+ 0(4 Q0    ( (2"?%2^$"(BE2<  $NM 0 1
M      "  4D>  !D,S R-3,Q9&5X.3DQ+FAT;5!+!08     !0 % $ !   -
%1@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
